Results 31 to 40 of about 5,929,149 (180)

Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High‐Risk Percutaneous Coronary Interventions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP).
Siyu Ma, Wendy Y. Cheng, Yinong Liang, Josephine Bryar, Gwyneth Wei, Joshua D. Niznik, Christina Yin, Sue Liu‐Yi, Jimmy L. Kerrigan   +8 more
wiley   +1 more source

Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience. [PDF]

, 2014
Plasma exchange (PEX) is a life-saving therapeutic procedure in patients with thrombotic thrombocytopaenic purpura (TTP) and other thrombotic microangiopathic anaemias (TMAs). However, it may be associated with significant complications, exacerbating the
McGuckin, S, Collier, D, Scully, M, Webster, H, Leverett, D, Westwood, JP   +5 more
core  

Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. [PDF]

, 2009
The activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome.
Hársfalvi, Jolán, Molvarec, Attila, Gombos, Tímea, Udvardy, Miklós László, Cervenak, László, Derzsy, Zoltán, Prohászka, Zoltán, Rigó, János, Bõze, Tamás, Makó, Veronika   +9 more
core   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Is Less More? An Update on Aspirin for Cancer Prevention in Lynch Syndrome From the Cancer Prevention Programme—CaPP

International Journal of Cancer, EarlyView.
ABSTRACT Aspirin has been used to treat pain and fever for 120 years. Its uses expanded into treating arthritis and prevention of thrombotic events. Its anti‐cancer role emerged with observational studies in the 1980's and subsequent cancer review in those treated with aspirin in cardiovascular trials.
John Burn, D. Timothy Bishop
wiley   +1 more source

Perinatal outcomes in normotensive versus hypertensive HELLP syndrome

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare maternal and neonatal outcomes between women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome with and without associated hypertension. Methods This was a retrospective cohort study at a tertiary university‐affiliated medical center including all singleton HELLP cases >24 weeks gestation (January ...
Matan Anteby, Keren‐Or Wertheimer, Omri Dominsky, Liran Hiersch, Yariv Yogev   +4 more
wiley   +1 more source

Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper

International Journal of Gynecology &Obstetrics, EarlyView.
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto, Martha Gulati, Suvarna S. Khadilkar, Angela H. E. M. Maas, Federica Frezet, Gláucia Maria Moraes de Oliveira, Andrea R. Genazzani, Hema Divakar, Athena Poppas, on behalf of the World Heart Federation (WHF) and the International Federation of Gynecology and Obstetrics (FIGO)   +9 more
wiley   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Phenotypic and Genotypic Analysis of Two Rare Cases of ‐‐SEA/‐α4.3 HbH Disease

Journal of Clinical Laboratory Analysis, EarlyView.
We report two unrelated adult patients with rare deletional HbH disease (genotype ‐‐SEA/‐α4.3). This novel 4.3 kb deletion covering the HBA1 gene is accompanied by X‐Y‐Z segment recombination, which was identified by CycloneSEQ long‐read nanopore sequencing.
Weijia Yang, Xiaoyan Huang, Li Zhang, Xiaoqin Yang, Yaya Guo, Qingping Kang, Min Dou, Guijun Huang   +7 more
wiley   +1 more source

Post-thrombotic syndrome after total hip arthroplasty

, 2003
The prevalence of post-thrombotic syndrome was assessed in 46 patients at least six years following total hip arthroplasty. Patients were examined clinically and sonographically. Post-thrombotic syndrome was diagnosed on the basis of both sonographic and
M. Zenios, V. George, R.H. Helm
core   +1 more source